Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Communication about an Ongoing Safety Review of CellCept (mycophenolate mofetil) and Myfortic (mycophenolic acid)
This information reflects FDA's current analysis of data available to FDA concerning this drug. FDA intends to update this sheet when additional information or analyses become available.
FDA has completed its review of postmarketing reports of progressive multifocal leukoencephalopathy (PML) in patients who took CellCept and Myfortic. The prescribing information for CellCept and Myfortic now includes information on PML in the Warnings and Adverse Events sections. Roche and Novartis issued Dear Health Care Professional Letters on May 29, 2008 outlining the changes to the prescribing information.
This information reflects FDA's current analysis of available data concerning these drugs. FDA intends to update this document when additional information or analyses become available.